Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
7
88%
Ph phase_3
1
13%

Phase Distribution

0

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
7(87.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (87.5%)
Phase 31 (12.5%)

Trials by Status

terminated113%
completed675%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_2

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
completedphase_3

TroVax Renal Immunotherapy Survival Trial

NCT00397345
completedphase_2

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

NCT00083941
completedphase_2

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

NCT00325507
completedphase_2

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

NCT01556841
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01194960Phase 2

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Terminated
NCT00397345Phase 3

TroVax Renal Immunotherapy Survival Trial

Completed
NCT00083941Phase 2

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

Completed
NCT00325507Phase 2

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Completed
NCT01556841Phase 2

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Completed
NCT00448409Phase 2

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

Completed
NCT01569919Phase 2

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

Unknown
NCT00259844Phase 2

Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8